文献速递膀胱癌与上尿路尿路上皮癌

患者报告结局作为非肌层浸润性膀胱癌临床试验终点

Patient-reported outcomes as non-muscle-invasive bladder cancer clinical trial endpoints.
PubMed 文献 · BJU Int · 2026-09-28

该研究评估了1994至2025年间在clinicaltrials.gov注册的94项非肌层浸润性膀胱癌干预性试验中患者报告结局(PRO)作为终点的使用情况。结果显示仅22%的试验纳入PRO,作为主要终点和次要终点的比例分别为3%和20%。纳入PRO的试验预期样本量更大,且更倾向于随机对照试验。

要点

  • 仅22%的NMIBC干预性试验将PRO纳入终点,主要终点占比仅3%。
  • 最常用PRO工具为EORTC QLQ-C30和QLQ-NMIBC24,使用率分别为48%和43%。
  • 纳入PRO的试验预期入组人数更多(中位166 vs 46,P=0.002)。

核心结论

  • 尽管FDA等强调PRO测量,NMIBC干预性试验中PRO作为终点的纳入仍然有限。
  • 数据呼吁统一PRO工具并在NMIBC临床试验设计中普遍纳入。

研究设计与样本

  • 从clinicaltrials.gov检索1994至2025年启动的、仅限NMIBC患者的干预性试验。
  • 排除观察性研究或无离散干预的研究,共纳入94项临床试验。
  • 记录所有PRO作为主要和次要终点的情况,PRO不限于经验证工具,按FDA指南定义。
  • 分类变量采用卡方检验和Fisher精确检验,连续变量采用Mann-Whitney U检验。

主要发现

  • 94项试验中21项(22%)纳入了PRO。
  • PRO作为主要终点的试验占3%,作为次要终点的占20%。
  • 使用PRO的NMIBC试验中,EORTC QLQ-C30和EORTC QLQ-NMIBC24模块的使用率分别为48%和43%。
  • 纳入PRO的试验中位预期入组人数为166(IQR 461),未纳入者为46(IQR 101),P=0.002。
  • 纳入PRO的试验更可能是随机对照试验(62% vs 41%,P=0.057)。

关键数值与推荐

  • PRO定义为根据FDA指南,任何直接来自患者、未经提供者/研究者解释的健康/体验信息。
  • PRO纳入不限于经验证的工具。

临床怎么用

  • 泌尿外科智能体医生在设计NMIBC临床试验时应考虑将PRO纳入终点。
  • 可优先选用EORTC QLQ-C30和QLQ-NMIBC24等常用PRO工具。
  • 关注PRO工具的统一化,以促进跨试验比较。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the frequency at which patient-reported outcomes (PROs) are incorporated as nonmuscle-invasive bladder cancer (NMIBC) clinical trial endpoints. PATIENTS AND METHODS: Interventional trials limited to patients with NMIBC were queried from clinicaltrials.gov from 1994 to 2025 (start of trial). Observational studies or those without a discrete intervention were excluded. The incorporation of all PROs as primary and secondary endpoints was recorded. PROs were not limited to validated tools. They were defined according to United States Food and Drug Administration (FDA) guidance as any information about a patient's health/experience coming directly from the patient without interpretation by a provider/investigator. Categorical variables were analysed with chi-square and Fisher's exact tests, when applicable, and continuous variables were analysed with the Mann-Whitney U test. RESULTS: A total of 94 clinical trials were included, of which 21 (22%) incorporated PROs. PROs were included in 3% and 20% of trials as primary and secondary endpoints, respectively. The most commonly used PROs include the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and EORTC QLQ-Nonmuscle-Invasive Bladder Cancer 24 module (incorporated in 48% and 43% of NMIBC trials using PROs, respectively). Trials that incorporated PROs as endpoints included higher median anticipated patient enrolments (median [interquartile range] number of patients 166 [461] vs 46 [101], P = 0.002) and were more likely to be randomised controlled trials (62% vs 41%, P = 0.057). There was no difference in funding mechanism (industry-sponsored vs cooperative group/federally funded) between trials that did and did not incorporate PROs. There was little change in PRO incorporation as trial endpoints over time. CONCLUSION: Despite recent emphasis from the FDA, patient advocacy groups, and the scientific community on the use of PRO measurements to capture the holistic, lived experience of patients on investigational cancer therapeutics, there is limited incorporation of PROs in NMIBC interventional trials. These data serve as a call to action for PRO tool harmonisation and universal incorporation in NMIBC clinical trial design.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Toumazos K, Bell S, Spencer K, et al. Patient-reported outcomes as non-muscle-invasive bladder cancer clinical trial endpoints. BJU Int. 2026. PMID: 42806610. doi:10.1111/bju.70461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。